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Abstract
Cardiac hypertrophy is an adaptive response that normalizes wall stress and compensates for increased workload. It is accompanied by
distinct qualitative and quantitative changes in the expression of protein isoforms concerning contractility, intracellular Ca2q-homeostasis
and metabolism. Changes in the myosin subunit isoform expression improves contractility by an increase in force generation at a given
2q  2q .Ca -concentration increased Ca -sensitivity and by improving the economy of the chemo-mechanical transduction process per
 .amount of utilised ATP increased duty ratio . In the human atrium this is achieved by partial replacement of the endogenous fast myosin
by the ventricular slow-type heavy and light chains. In the hypertrophic human ventricle the slow-type b-myosin heavy chains remain
 .unchanged, but the ectopic expression of the atrial myosin essential light chain ALC1 partially replaces the endogenous ventricular
 .isoform VLC1 . The ventricular contractile apparatus with myosin containing ALC1 is characterised by faster cross-bridge kinetics, a
higher Ca2q-sensitivity of force generation and an increased duty ratio. The mechanism for cross-bridge modulation relies on the extended
Ala–Pro-rich N-terminus of the essential light chains of which the first eleven residues interact with the C-terminus of actin. A change in
charge in this region between ALC1 and VLC1 explains their functional difference. The intracellular Ca2q-handling may be impaired in
heart failure, resulting in either higher or lower cytosolic Ca2q-levels. Thus the state of the cardiomyocyte determines whether this
hypertrophic adaptation remains beneficial or becomes detrimental during failure. Also discussed are the effects on contractility of
long-term changes in isoform expression of other sarcomeric proteins. Positive and negative modulation of contractility by short-term
phosphorylation reactions at multiple sites in the myosin regulatory light chain, troponin-I, troponin-T, a-tropomyosin and myosin
binding protein-C are considered in detail. q 1998 Elsevier Science B.V.
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1. Introduction
Heart muscle performs work with high contractile effi-
w xciency 1,2 . Under increased workload it reacts with hy-
pertrophy. This represents an adaptive response in order to
normalise wall stress and compensate for the increased
w xhemodynamic load 3 . When the load is chronically ele-
vated, compensated hypertrophy may progress to pump
failure. Except in the case of acute global ischemia which
is accompanied by a collapse of energy production, it is
not clear which process, or processes, are responsible for
)  .  .Corresponding author. Tel.: q41-1 635 5919; fax: q41-1 635
5708; e-mail: schaub@pharma.unizh.ch
turning compensated hypertrophy into heart failure. Nu-
merous physiological characteristics concerning
metabolism, contractility and cellular structure are found to
be impaired in heart failure. However, contractile function
is often preserved or even improved in hypertrophy as well
as in failure when studied at the subcellular level, i.e. on
permeabilised muscle fibers or on isolated proteins in the
in vitro motility assay and in solution studies.
 .The changes in the contractile apparatus Figs. 1 and 2
result from long-lasting changes in the gene expression
 w x.program reviewed in 4,5 . Because cardiomyocytes are
Time for primary review 26 days.
0008-6363r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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Fig. 1. Scheme of the cardiac sarcomere in relation to the membranous structures responsible for the intracellular Ca2q-handling. TT, transverse tubule;
 2q .TC, terminal cisternae; DHPR, dihydropyridine receptor voltage sensor and slow inward Ca -channel at the TT membrane; RyR, ryanodine receptor
 2q . w xCa -release channel of the SR with foot structures at the TC membrane 183 . M-line consists of myomesin, 165 kDa M-line protein and creatine
w xkinase; Z-line contains mainly a-actinin, desmin and CapZ protein 32 . MyPB-C localizes to the eleven transverse stripes on either side of the M-line and
binds to myosin and titin. Titin is anchored with its N-terminus at the Z-line and, running along the myosin filament, reaches the M-line with its C-terminal
head portion where it interacts with myomesin and the M-line protein. Two nebulette molecules are associated with each actin filament, which originate
w xwith their C-terminus from the Z-line, and Tropomodulin caps the actin filaments at their pointed end 5 .
no longer able to increase muscle mass by proliferation
they resort to hypertrophy. Hypertrophy does not mean
more of the same but involves specific qualitative alter-
w xations in the cell phenotype 5–7 . Reexpression of ‘fetal
genes’ which are normally active in the fetal period coding
 . for proteins such as b-myosin heavy chain b-MHC see
.Table 1 for abbreviations , a-skeletal and a-smooth mus-
cle actin or atrial natriuretic factor, may occur. The devel-
opment of hypertrophy in humans is a slow and chronic
process extending over years. However, the long-term
changes in expression of contractile proteins is not simply
a reactivation of the ‘fetal gene program’, but follows a
pattern that seems to be determined by the physiological
demands. These physiological demands are transmitted by
a panoply of different stimuli, besides mechanical loading,
involving hormones, catecholamines, growth factors, cy-
 w x.tokines and vasoactive peptides reviewed in 8 . Most of
these hypertrophic stimuli use different intracellular signal-
ing pathways which results in individual phenotypic re-
sponses as characterised by gene expression pattern, cell
morphology and function. The effects of various hyper-
trophic stimuli are likely to be balanced in vivo, even
during compensatory hypertrophy. However, the distur-
bance of any single factor may tip this balance for the
worse. The precise knowledge of the function of the
contractile apparatus including its regulatory mechanisms
in the normal heart and during hypertrophy is indispens-
able when considering potential therapeutic strategies
aimed at avoiding development of heart failure.
The purpose of this review is to put together recently
published results on the structure and function of the
 .myosin light chain MLC isoforms whose expression
changes during the development of cardiac hypertrophy.
The discussion includes the position and relation of the
MLC in the myosin head next to the motor domain, the
variation in MHC and MLC isoforms and their possible
hybrid molecular assemblies in atrial and ventricular mus-
cles. The knowledge how calcium controls the myosin
cross-bridge kinetics is instrumental in delineating the
 .details of the mechanism by which the atrial MLC1 ALC1
positively affects contractility of the ventricular muscle.
The pathophysiological consequences of the expression of
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Fig. 2. Schematic detail of the sarcomere with the proteins affecting
contractility and which are described in the text. AF, thin actin filament;
 . 2q  .MF, thick myosin filament; inhibitory TnI , Ca -binding TnC and
 .tropomyosin binding TnT troponin components; S1, myosin subfrag-
 .ment-1 myosin head portion ; ELC and RLC, essential and regulatory
myosin light chains; MyBP-C, hypothetical localization of the myosin
binding protein-C spaced 43 nm apart along the myosin filament. The
M-line would be to the left and the Z-line to the right.
the ALC1 are discussed in view of the functional viability
of the cardiomyocyte with regard to intracellular Ca2q-
handling and energy supply during hypertrophy and in
heart failure. In order to recognize the relevance of modu-
lation of contractility by myosin essential light chain, we
give an overview of other sarcomeric proteins associated
with the contractile machinery and point out the role of
protein phosphorylation in Ca2q-sensitivity and cross-
bridge kinetics. Taken together, we provide evidence for
the functional significance of the change in MLC isoform
expression in the human heart ventricle where the MHC
remain unaltered during hypertrophy. In view of space
limitation, reviews which contain references to primary
information are often cited.
2. The myosin motor
 .The myosin muscle motor myosin type-II is a hexam-
 .eric protein 520 kDa consisting of two heavy chains
 . MHC of around 220 kDa 1930–1940 amino acid
.  .residues and of two pairs of light chains MLC of around
20 kDa each. The MHC subunits, which provide both the
motor and the filament forming properties, can each be
divided into two functional domains: the globular N-termi-
nal head domain corresponding to the proteolytic subfrag-
.ment-1 or S1 of 120 kDa and the elongated a-helical
domain that, together with the corresponding domain of
the second MHC, forms the coiled coil C-terminal rod
 .Fig. 2 . The S1 has an approximate length of 16.5 nm and
the rod domain one of 140 nm. The S1 domain can be
 .further subdivided into two parts, i the motor domain,
running from the N-terminus through to residue 770 and
containing the nucleotide binding pocket and the actin
 .binding cleft, and ii the 8 nm long a-helical light chain
 .binding or regulatory domain neck region which extends
from residue 771 to residue 843 and links the motor
w x  .domain to the rod domain 9,10 Fig. 3 . The a-helix of
this regulatory domain is stabilized by non-covalent associ-
ation of one MLC of each type. Near its C-terminus the
a-helix bends sharply at the residues W829–P830–W831
and this last stretch of the a-helix points along the myosin
filament axis towards the middle of the sarcomere, before
it joins the second MHC in the rod. The precise interac-
tions of the MLC with the MHC in this region have been
w xrevealed by crystal structures of the chicken S1 9 and of
the regulatory domain of the molluscan scallop myosin
w x11 . The two MLC are located in series and are wrapped
around the MHC in an anti-parallel orientation. In the
 .chicken S1, MLC type-1 essential light chain binds to
residues from L783 to M806 and MLC type-2 regulatory
. w xlight chain to residues from E808 to L842 of MHC 9 . It
Table 1
Abbreviations, names and explanations
2q .A1, atrial aa -MHC myosin pCa, negative decadic logarithm of the free Ca -concentration
 .A2, atrial bb -MHC myosin PKA, protein kinase-A
ALC1, atrial myosin essential light chain PKC, protein kinase-C
ALC2, atrial myosin regulatory light chain RLC, myosin regulatory light chain
2q  .CAMK, Ca -calmodulin dependent protein kinase S1, myosin subfragment-1 myosin head portion
cAMP, cyclic adenosine monophosphate SDS-PAGE, sodium dodecylsulfate polyacrylamide gel electrophoresis
2qDCM, dilated cardiomyopathy SERCA2, cardiac Ca -pump of the SR
DTNB, dithiobis-nitrobenzoic acid SR, sarcoplasmic reticulum
EF, ejection fraction Tm, tropomyosin
2qEF-hand, Ca -binding helix–loop–helix motif Tn, troponin complex
2qELC, myosin essential light chain TnC, Ca -binding Tn component
FHC, familial hypertrophic cardiomyopathy TnI, inhibitory Tn component
ICM, ischemic cardiomyopathy TnT, Tm-binding Tn component
 .MHC, myosin heavy chain V1, ventricular aa -MHC myosin
 .MLC, myosin light chain V2, ventricular ab -MHC myosin
 .MLCK, myosin light chain kinase V3, ventricular bb -MHC myosin
MyBP-C, myosin-binding protein-C VLC1, ventricular myosin essential light chain
NYHA, New York heart association classification VLC2, ventricular myosin regulatory light chain
Single amino acid residues are given by the three-letter code and protein sequences in the one-letter code.
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Fig. 3. Schematic drawing, approximately to scale, of the interactions of
 .the myosin head subfragment-1 with the actin filament. The myosin
 .motor domain hatched displays the ATP binding pocket and the actin
 .  .binding cleft. The upper U and lower L portions of the 50 kDa
segment are interacting with two adjacent actin monomers. MHC denotes
the a-helix which constitutes the regulatory domain with the two bound
 .light chains ELC and RLC . The extended N-terminus of the ELC1
reaches to the proximate actin. This state represents the rigor conforma-
w xtion as modeled from the crystal structure 23 . The Z-line would be to
the left and the M-line to the right. For further details see text.
has been agreed to give the position numbers for amino
acids in the sequence of the chicken skeletal muscle MHC
even when referring to mammalian skeletal or heart mus-
w xcle myosins 12,13 .
Myosin cross-bridges myosin head portions protruding
.from the myosin filament provoke movement during con-
traction by repetitive interactions with the actin filament in
the sarcomere. Thereby the cross-bridges are thought to
swing through a number of power strokes, each time
displacing the two filaments relative to one another by a
w xdistance of 5 to 10 nm 14,15 . Recent studies on time-re-
w xsolved X-ray diffraction of live frog sartorius muscles 16
and fluorescence polarisation coupled with rapid length
steps imposed on permeabilised rabbit psoas fibers mech-
. w xanically or chemically skinned fibers 17 , show attach-
ment of cross-bridges with actin and synchronized head
movements in the elementary force-generating process.
However, the rowing cross-bridge model as accepted in the
w xtextbooks since 1971 18 requires an update. The tip of
the motor domain is now envisaged to bind actin with a
more or less fixed geometry throughout the power stroke,
while it is the distal C-terminal light chain binding region
w xof the myosin molecule that actually moves 10,17,19 .
The a-helix of this regulatory domain serves as a ‘lever
arm’ to amplify relatively restricted rotational movements
among different structural parts within the motor domain.
It was shown that the length of the lever arm is directly
proportional to the sliding velocity in an in vitro motility
w xassay system 20 . For this purpose, the lever arm of the S1
domain of myosin-II from the slime mould Dictyostelium
discoideum, a myosin that is homologous to vertebrate
striated muscle myosin, was altered in length by addition
or subtraction of light chain binding regions by genetic
engineering. The advent of nano-technology has recently
allowed to determine discrete stepwise movement averag-
ing 11 nm under low load and single force transients
averaging 3 to 4 pN under isometric conditions of rabbit
w xfast skeletal muscle myosin 21 . In this case, myosin
molecules were fixed on silica beads and one molecule
was let to interact with an actin filament held at both ends
by a feedback enhanced laser trap system.
X-ray structural data of the individual proteins together
with data obtained by fiber diffraction and electron mi-
croscopy have been used to build detailed models of the
w xrigor interaction of myosin with the actin filament 22–24 .
In the contracting muscle this state is thought to occur
transiently at the end of the power stroke after release of
the products Pi and ADP before a new substrate ATP
molecule gets bound to myosin. In the rigor state one
myosin head is suggested to interact with two adjacent
 .actin monomers Fig. 3 . A number of hydrophobic residues
on the opposing faces of actin and myosin contribute to the
main contacts. These contacts are flanked by charged
myosin surface loops which form predominantly ionic
interactions with adjacent regions of actin. Two such loops
represent the connector regions between the segments of
the MHC of S1 that can be obtained by proteolysis with
trypsin, i.e. the 25-kDa, 50-kDa and 20-kDa segments
w xstarting from the N-terminus 25 . These loops exhibit
considerable sequence variability and it appears that their
composition influences the kinetic behavior of myosin
from different sources. Replacement of the 50–20-loop in
Dictyostelium myosin with the equivalent myosin se-
quence from rabbit fast skeletal, chicken smooth or rat
cardiac muscle leads to an actin activated ATPase activity
that corresponds to the one of the respective parent myosin
w x25 . The 25–50-loop has been suggested to affect the
release of ADP from the nucleotide binding pocket and
thus may be responsible for the observed differences in
w xmotility between different myosins 26 . In addition, and as
discussed in the section on MLC below, the N-terminus of
the large isoform of the essential MLC1 has also been
shown to interact with the C-terminus of an actin monomer
 .Fig. 3 and to affect the actin activated ATPase activity.
3. Cardiac myosin heavy chains
At least eight different MHC types are expressed in
mammalian striated muscles: two developmental isoforms
 .MHC-embryonic and MHC-perinatal , four fast isoforms
 .MHC-fast 2A, 2B, 2XrD and MHC-extraocular as well
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as MHC-slow which is identical to the cardiac b-MHC. In
addition, the heart also expresses the cardiac a-MHC
 w x.isoform for review see 27 . The human a-MHC contains
w x w x1939 28 and the b-MHC 1935 29 amino acid residues.
Among them they share 93.1% sequence identity. The rat
w xa-MHC contains 1938 and the b-MHC 1935 residues 30 ,
and they share 93.2% sequence identity. A total of 131
residues differ between them and most of these differences
are confined to regions of biological significance in the S1
subfragment such as the N-terminus, the ATP binding
pocket, the actin binding cleft, the light chain binding
domain and in the two hinge regions further down in the
rod domain. In inter-species comparison between human
and rat, a-MHC shows over 97% sequence identity. The
same holds for b-MHC.
During development and under pathophysiological con-
ditions, the expression of the two cardiac MHC isoforms is
regulated in a tissue-specific manner. Their expression is
under additional hormonal control, notably by thyroid
w xhormones 5,31,32 . In all mammalian species a-MHC is
expressed in the atria throughout life. In small mammals
such as rat and mouse, a-MHC is also the predominant
isoform in the ventricles post partum and during adult-
hood. In addition, a-MHC is expressed in extraocular
muscles as well as in some mandibular muscles of carni-
vores. b-MHC is expressed in the embryonicrfetal ventri-
cles of all mammals and disappears soon after birth in
small animal species. In larger animals such as rabbit, dog,
pig and human, b-MHC remains the predominant ventricu-
 .lar isoform throughout adulthood Table 2 .
The fact that the b-MHC is also expressed in skeletal
muscle fibers of the slow type-1 allows to perform func-
tional studies on mutated b-MHC from patients with famil-
 .ial hypertrophic cardiomyopathy FHC . In the in vitro
motility assay of purified myosin from the soleus muscle
of FHC patients with seven different point mutations in the
b-MHC gene, the velocity of actin translocation was on
average about half or less than that of myosin from healthy
 y1 . w xcontrol persons average control value 0.48 mm s 33 .
In addition, myosin prepared from interventricular septal
sites as well as from the soleus muscle of FHC patients
 .with the R403Q position 405 in chicken mutation exhib-
 y1ited the same low motility 0.11 and 0.13 mm s , respec-
.tively . Permeabilised slow fibers from the soleus muscle
of FHC patients with either the R403Q or G741R position
.743 in chicken mutations also showed impaired contrac-
tile functions, although the fraction of mutant MHC in
w xthese fibers was not known 34 .
4. Cardiac myosin light chains
 .The myosin light chains MLC comprise two subfami-
 .lies, the essential light chains ELC and the regulatory
 .light chains RLC . Both MLC subfamilies belong, to-
gether with the calmodulin and the troponin-C subfamilies,
to the superfamily of intracellular Ca2q-binding proteins
that characteristically contain four EF-hand domains
 . w xhelix–loop–helix motif 35 . However, during evolution,
all four EF-domains of vertebrate muscle myosin ELC
have lost their ability to bind Ca2q, while in the case of the
RLC only the first EF-domain can bind either Ca2q or
Mg2q with high affinity in situ in the myosin molecule
 7 y1. w xbinding affinities in the range of 10 M 36 . The ELC
is called ‘essential’ because it was originally thought to be
essential for the hydrolytic activity of myosin; but later,
w xthis proved not to be the case 37,38 . Alternative names
are alkali MLC since ELC can be removed from myosin
.by elevated pH or MLC1. The RLC is termed ‘regulatory’
because in vertebrate smooth muscle and non-muscle cells,
contractile activity is triggered by phosphorylation of this
w xmyosin light chain 39 . Alternative names are DTNB-MLC
since it can be removed from myosin by DTNB-treat-
.  .ment , PLC it can be reversibly phosphorylated or MLC2.
The ATPase activity of isolated myosin does not seem to
be affected by the ELC or RLC. It has however become
increasingly evident, that within the complex sarcomeric
structure, the MLC are involved in the fine-tuning of the
contractile activity.
Table 2
 .Myosin heavy chain MHC and MLC1 isoform composition in all four chambers of six explanted hearts from patients with end-stage heart failure
compared to five hearts from patients with compensated hemodynamics. Muscle specimens were obtained from the free wall of all four heart chambers.
w xRelative content of MHC and MLC1 was densitometrically evaluated after electrophoretic resolution 68,69 . Type of disease and functional state of the
patients is given in the text. Average percentages"SEM are given
Heart condition Protein isoform Right atrium Left atrium Right ventricle Left ventricle
Compensated hearts a-MHC 90"2.1 93"3.4 -3 -3
b-MHC 10"2.1 7"3.4 100 100
ALC1 100 100 -1 -1
VLC1 -1 -1 100 100
Failing hearts a-MHC 52"9 56" -3 -3
b-MHC 48"9 44"9 100 100
ALC1 90.3"2.1 91.9"3.3 5.5"1.4 7.8"4.4
VLC1 9.7"2.1 8.1"3.3 94.5"1.4 92.2"4.4
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Two varieties of ELC and RLC are expressed in the
heart, characteristic for the atrial and the ventricular tis-
sues. They are thus designated ALC1 and VLC1 for atrial
and ventricular ELC, respectively, and ALC2 and VLC2
for the corresponding RLC species. ALC1 and VLC1
 .  .human and rat contain 190–200 Table 3 and the VLC2
around 165 amino acid residues no data available for
. w xALC2 35 . The molecular mass for the MLC1 and MLC2
types is around 22 and 19 kDa, respectively. However, the
MLC1 migrates with a higher apparent mass of around 27
kDa in SDS gel-electrophoresis because of its particular
N-terminus. The most striking difference between the two
types of MLC concerns an additional peptide stretch of
around 30 residues at the N-terminus of the ELC. An
unusual accumulation of around 10 Ala and 10 Pro is
found in this extra stretch. In addition, several positively
and negatively charged amino acid residues are clustered
 .near the N-terminus Table 3 . Such sequences rich in Ala
w xand Pro form rigid extended structures 40 . It has been
shown by biochemical in solution studies that the N-
 .terminus of fast skeletal muscle ELC ELC1fast binds to
w xthe C-terminus of actin 41,42 . This extended N-terminal
structure of the ELC1fast cannot be seen in the crystal
w xstructure of the chicken S1 subfragment 9 . The last
visible residue in the fast skeletal muscle ELC corresponds
to positions 46–53 in the sequences of human and rat
ALC1 and VLC1, and this residue lies roughly in the
centre of the 3-dimensional structure of the ELC at a
distance of 7–8 nm from the actin filament surface. Thus a
stretch of around 50 residues is available for the N-terminus
of ALC1 and VLC1 to bridge the gap of 7–8 nm and to
contact the actin filament. In principle, only 24 residues
are required to span a distance of 8 nm if present in an
extended b-sheet conformation. Taken together, the odd 50
N-terminal residues in ALC1 and VLC1 are ample to run
along the myosin head moiety and to interact with a
 . w xproximate actin monomer Fig. 3 24 . It has recently been
shown that the first 11 N-terminal residues of human
ALC1 are responsible for binding to the actin C-terminus
w x43 . The interaction of the N-terminus of ELC has indeed
been shown to affect contractility and actin activated AT-
Pase activity in skeletal muscle protein systems for re-
w x.views see 44–47 . It is this structural feature that seems
to be of relevance for the pathophysiological aspects of
cardiac hypertrophy discussed below. Interestingly, all ELC
isoforms expressed in vertebrate striated muscles have
such an extended N-terminus that is found neither in
invertebrate ELC nor in the vertebrate smooth and non-
muscle myosin ELC.
The ALC1 is identical to the embryonic ELC1emb
which is also transiently expressed in fetal skeletal muscles
w xas well as in fetal ventricular heart tissue 48 . On the other
hand, the VLC1 is identical to the skeletal muscle
ELC1bslow which is expressed in adult slow skeletal
w xmuscles 49 . VLC2 is also expressed in adult slow skeletal
muscles as RLC2slow. An additional ventricular RLC
designated VLC2) that has a different isoelectric point but
the same mass as VLC2 and can be resolved by 2-dimen-
 .sional gel electrophoresis Fig. 4 , is found in ventricles of
w xmost mammals 50,51 . Both VLC2 varieties have differ-
ent amino acid sequences and each contains one phospho-
rylation site for a Ca2q-calmodulin dependent light chain
 . w xkinase MLCK 52 . In contrast, the sole ALC2 variety in
the human atrium can be phosphorylated at two sites. The
significance of this feature for cardiac contractility is,
w xhowever, not known 53 .
Table 3
 .Amino acid sequence and charge distribution of the first 20 residues of the pre-domain of the myosin light chain type-1 MLC1 from human and rat
w xcardiac and fast skeletal muscles. Numbering is based on the mature protein, neglecting the N-terminal Met 47 . Following the pre-domain, the rest of the
MLC1 comprises the four EF-domains with their respective interdomains and end with the last residue of the fourth EF-domain this part contains 143
.amino acid residues in each case . For comparison the charge distribution is also given for the last 20 residues in the sequence of mammalian cardiac
w xa-actin. Bold characters represent residues with positive charge; outline characters represent residues with negative charge. Data taken from Refs. 35,184
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Fig. 4. Schematic drawing of the myosin light chains and a-tropomyosin
 .TM resolved by two-dimensional gel electrophoresis from the ventricle
of patients with hypertrophy andror end-stage heart failure. First dimen-
sion, isoelectric focusing and second dimension in SDS with decreasing
 .  .molecular mass. U unphosphorylated and P phosphorylated form of
) a-tropomyosin. Both VLC2 and VLC2 can be phosphorylated large
.and small open symbols, respectively . Atrial ALC1 is present in addition
w xto the endogenous VLC1 63,68,69 . For further details see text.
Several recently detected missense point mutations in
either the ELC or RLC are associated with a rare variant of
w xFHC and with skeletal muscle myopathy 54 . In contrast
to most mutations in the MHC of FHC patients which are
w xassociated with impaired motility 33 , myosin from a
patient with the M149V mutation in the VLC1 displayed
an actin filament translocation velocity that was increased
by 41% as compared to control myosin. The two mutations
M149V and R154H found in the VLC1 are localized in the
region where it contacts the motor domain of the MHC.
This putative interaction may correspond to the base around
 .which the regulatory domain lever arm moves during
 . w xcontraction Fig. 3 10 . Furthermore, three mutations in
 .the VLC2 A13T, E22K and P94R all seem to be local-
w xized near the phosphorylation site at S15 54 .
5. Combinatorial associations of multiple myosin iso-
form subunits
It is known that the different isoforms of MHC as well
as of MLC are responsible for distinct contractile proper-
ties. Therefore it is difficult to accept the idea that this
isoform variety simply reflects an evolutionary relict of
progredient accumulation of gene duplications, mutations
and chromosomal rearrangements. The strict regulation
during development and tissue-specific mode of expression
seems more likely to favor the notion that the various
isoforms present a store from which to choose in order to
build molecular motors with functional isoform advan-
tages. It might therefore be useful to consider the different
heteromeric molecular assemblies that may possibly occur
under normal and under pathological conditions.
Under normal conditions in adult human hearts the
a-MHC together with ALC1 and ALC2 are confined to the
atrium, while the b-MHC together with VLC1, VLC2 and
VLC2) are to be found in the ventricles. Some b-MHC
 .seems to accumulate in atria with increasing age Table 2 ,
which in the atrial appendages may reach values up to
w x50% of total MHC 55–57 . However, pressure overload
models in animals as well as hemodynamic overload in
humans leads to characteristic changes in myosin composi-
tion in both atria and ventricles. The ventricular myosin
subunit isoforms VLC1 and VLC2 become ectopically
expressed in atria in small mammals as well as in humans
w x31,58 . b-MHC increases in human atria up to 50% or
 . w xmore Table 2 56 and becomes reexpressed in ventricles
of small animals which normally display predominantly
a-MHC. In normal human ventricles a small amount of
a-MHC, estimated to vary between low levels and 10%,
w xcan be observed beside the abundant b-MHC 59–62 .
This residual pool of a-MHC is absent in patients under
hemodynamic overload. Electrophoretic resolution of na-
tive myosin isolated from ventricles of hemodynamically
overloaded small animals with varying proportions of a-
MHC and b-MHC yields three species designated V1, V2
and V3 according to electrophoretic mobility. V1 and V3
consist of homodimeric aa and bb combinations, respec-
tively, and V2 represents the heterodimer ab. Interest-
ingly, myosin from overloaded atria resolves into two
 .  .species only, namely A1 aa and A2 bb . A1 and A2
do not co-migrate exactly with the corresponding ventricu-
lar species V1 and V3, because they contain different
w xMLC complements 31 .
In normal human atria, two MHC homodimers aa and
.bb together with ALC1 and ALC2 give rise to two
myosin isoforms. In hemodynamically overloaded human
atria, we are confronted with the co-existence of the two
MHC homodimers with two types of MLC ALC1 and
.ALC2 as well as VLC1 and VLC2 . Both MHC homod-
imers may combine with each MLC type in three ways
forming two homodimers and one heterodimer with regard
to the MLC ALC1rALC1, VLC1rVLC1 and
ALC1rVLC1 as well as ALC2rALC2, VLC2rVLC2 and
.ALC2rVLC2 . Combinatorially, this allows for 2=3=3
s18 different myosin species. Since both MLC1 and
MLC2 are present in two different isoforms, the sequential
arrangement along one MHC may also play a role. Two
sequential arrangements are possible in one myosin
molecule: VLC1–VLC2rALC1–ALC2 as well as VLC1–
ALC2rALC1–VLC2. Therefore, one additional species
 .has to be added for each MHC homodimer aa and bb
making a total of 20 instead of 18 isoforms. This number
would increase even to 42 if the ventricular VLC2) were
also considered. This isoform has been shown to be ex-
pressed in a proportion of VLC2) to VLC2 of around 0.4
w xin control as well as in overloaded human ventricles 63 .
VLC2) has been shown to occur also in significant
w xamounts in overloaded human atria 64 . In any case,
multiple possible myosin isoforms could account for the
w xaltered contractility of diseased atrium 65,66 when com-
pared to normal atrium.
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In normal human ventricle, mainly b-MHC and a small
amount of a-MHC beside the VLC1 and two types of
 ) .MLC2 VLC2 and VLC2 are present. Ignoring the rare
a-MHC, this would give rise to three myosin isoforms
containing V LC2r V LC 2, V LC 2r V LC 2 ) or
VLC2)rVLC2 ). As mentioned above, most of the a-
MHC disappears under hemodynamic overload, leaving
only the b-MHC species. However, we have reported that
under such conditions the ALC1 becomes reexpressed in
the ventricle varying in amounts up to 30% of total MLC1
 . w xFig. 4 and Table 2 67–69 . Therefore, in diseased
human ventricle the bb-homodimer may combine with
either VLC1 andror ALC1 to form two homodimers
 .VLC1rVLC1 or ALC1rALC1 and the heterodimer
VLC1rALC1. The same type of combinations are, of
course, also possible with regard to the VLC2 and VLC2).
Thus, in the diseased human ventricle as many as 1=3=
3s9 myosin isoforms may co-exist. The combination
with four different MLC in one molecule allows also in
this case two possible sequential alignments on the MHC.
This brings the total number of possible isoforms in the
overloaded ventricle to 10 instead of 9.
As discussed below, shifts in expression of cardiac
MHC as well as MLC are known to affect the contractile
properties. In order to form heterodimeric molecules, the
corresponding isoform subunits must be expressed in the
same cell. This seems to be the case for ventricular
myocytes as probed with monoclonal antibodies against
w xa-MHC and b-MHC 62,70 . Atrial myocytes have also
w xbeen shown to co-express a-MHC and b-MHC 55 ; nev-
ertheless, MHC heterodimers are not observed in atrial
tissue. Whether or not all possible subunit associations
discussed above are actually realized in vivo is not known.
Functional myosin requires a strict stoichiometric relation
of its subunits. The parallel occurrence of b-MHC and
VLC2 in the atria of hypertensive baboons was taken to
w xindicate a coordinated expression of myosin subunits 71 .
However, cardiac MLC exhibit a slower turnover rate than
w xMHC 72,73 . Consequently there is a pool of unassembled
MLC in the cytoplasm. In accordance, we found an excess
of around 0.8 molar of VLC1 over MHC in human ventri-
w xcle 69 . The additional expression of ALC1 in hyper-
trophic ventricles added up to an excess of 3.5 molar of
 .total MLC1 VLC1 plus ALC1 over MHC. Isolation and
analysis of myosin from such tissue indicated that, com-
pared to VLC1, the proportional contribution of ALC1
bound to bb-myosin was roughly the same as its content
in total tissue samples. In contrast, in transgenic mice
ectopically expressing the skeletal myosin ELC2fast, in-
corporation into cardiac myosin was not proportional to
w xthe total amount actually expressed 74 . While in atria the
foreign ELC2fast replaced the endogenous ALC2 almost
entirely, this hardly occurred in the ventricles, despite the
fact that in both tissues aa-myosin was the recipient
protein. These cases illustrate that human ventricular bb-
myosin readily combines with ALC1 and that murine atrial
aa-myosin accepts skeletal muscle ELC2fast while its
 .ventricular counterpart also aa-myosin does not. It may
thus be emphasised that correlated regulation of expression
of MHC and MLC is not required for stoichiometric
assembly. In general, synthesis of MLC may be in excess
over that of MHC and a large portion of the unassembled
MLC will probably be degraded. On the other hand, we
observed a far larger amount of b-MHC in whole tissue
samples of hemodynamically overloaded human atria than
 .VLC1 Table 2 .
A further aspect may shed some light on the question of
heteromeric myosin assemblies. During development the
expression of MHC and MLC isoforms undergoes transi-
tions in atria and ventricle which are temporally not closely
w xlinked 57 . This implies a lack of isotype-specific interac-
tions between the MHC and MLC. Taken together, the
available evidence suggests that different MLC can indeed
combine with different MHC. Furthermore, the MHC and
MLC may be regulated independently of one another and
thus allow for a variety of mixed isotype assemblies to
occur in vivo.
6. Myosin cross-bridge kinetics
Cardiac contractility is directly related to the type of
predominant myosin species. The motor protein defines the
frame within which contractility may vary in terms of
 .force production unitary force per cross-bridge cycle and
 .velocity of displacement kinetics . The structural and
mechanical changes in the cross-bridge a series of succes-
.sive conformational changes in the myosin head domain
are coupled to a concomitant series of chemical reactions
involving the hydrolysis of ATP to ADP and inorganic
 w x.phosphate confer 75,76 . The simplified scheme in Fig.
5 combines the mechanical and kinetic cycles and delin-
eates the main intermediate states in the actin–myosin
 .  .cross-bridge cycle. The affinity of myosin M to actin A
changes during the cross-bridge cycle. The species with
bound ATP or its products resulting from hydrolysis ADP
.and Pi exhibit low affinity, do not produce force and
 .oscillate rapidly on a time scale of ms or less between
attached and detached states. Consequently, they do not
present significant resistance to stretch of relaxed muscle.
Fig. 5. Simplified kinetic scheme of the cross-bridge cycle. M, myosin;
A, actin. Main reaction pathways are indicated by heavy arrows. For
explanations see text.
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Force production is thought to be coupled to the release of
Pi and comprises the transition from weakly to strongly
w xbinding states 77,78 . These force generating cross-bridges
exhibit a slower rate of oscillation between attachment and
detachment bind to actin with positive cooperativity. This
results in an increased resistance to passive stretch. The
complete cross-bridge cycle is terminated in the nu-
cleotide-free state after dissociation of ADP which resem-
bles the state of rigor mortis. In vivo, upon binding of a
new substrate ATP, the cross-bridge dissociates from actin
and the cycle is ready to start again.
Measurements of contractile parameters such as isomet-
ric tension, shortening velocity and force redevelopment
following a brief period of shortening at zero load can
provide information about the distribution of cross-bridges
among weakly and strongly binding states and the kinetics
w xof transitions between them 79 . The first quantitative
model which related experimental parameters to the kinet-
ics of the cross-bridge cycle considered two states: one
attached and force-generating, and one detached non-
w xforce-generating 80 . These two states are related by two
rate constants: the forward rate constant f determining the
rate of attachment, and the forward rate constant g deter-
mining the rate of detachment. The same model is now
applied to the reaction scheme with many intermediate
w xcross-bridge states 76 . In analogy to the original model,
the rate constant f now describes the transition fromapp
weakly binding, non-force generating states, to the strongly
binding, force-generating states, and g describes thatapp
for the opposite transition via product release and rebind-
 .ing of ATP Fig. 5 . Since weakly binding non-force-gen-
erating cross-bridges are still in rapid equilibrium with
w xactin 81 , the rate constants no longer describe attachment
 .and detachment, respectively. The isometric force F of a
muscle can thus be described as
fappXFsF Pn Ptot f qgapp app
X  .where F is the force unitary force generated per cross-
bridge and n is the total amount of cycling cross-bridgestot
 .per half-sarcomere. The expression f r f qg rep-app app app
resents the fraction of cycling cross-bridges in the force-
generating states, and hence, steady-state tension. Both an
increase in f or a decrease in g will increase theapp app
fraction of force-generating cross-bridges and, therefore,
increase tension generation of a muscle. The rate of transi-
tion from weakly to strongly binding states may be esti-
mated from the rate of tension development after a brief
w xshortening at zero load 76,82 . The rate constant of ten-
 .  .sion redevelopment k equals f qg . The un-td app app
 .loaded maximal shortening velocity V primarily de-max
pends on g which, in turn, is controlled by the releaseapp
w xof ADP 83 . The ATPase activity during isometric
w xsteady-state tension can be described by the equation 82
ATPasesn PsP f Pg r f qg .tot app app app app
where s is the number of half sarcomeres. Tension cost is
then obtained by dividing the ATPase-equation by the
force-equation yielding g P srFX. Under isometricapp
steady-state conditions s is constant, and if FX is equal
between two myosin isoforms under consideration, then
the relation of ATPase activity and tension may be directly
proportional to g . An increase in g would predict aapp app
decrease in force, and vice versa.
To illustrate the complexity of the interrelation between
the mechanical and kinetic properties of contractility, let us
consider a muscle fiber that is stimulated to contract. The
amount of force produced depends on how it is free to
move. The velocity at which the fiber shortens depends on
how great a load it must bear. If no load is applied, the
 .fiber shortens at the maximal speed V . If a forcemax
sufficient to prevent shortening is applied, the fiber devel-
ops force under isometric conditions. Whatever parameter
one measures, and regardless of how it is measured, the
results are not only determined by the intrinsic properties
of the motor protein alone, but also by the continuously
varying mechanical conditions imposed on the system by
the reaction partner actin as well as by the regulatory
proteins in the sarcomere. This complex ensemble is re-
w xflected in the force–velocity relation 32,79 . In perform-
ing work against a load, muscle generates power, which is
work per unit of time and is obtained by multiplying force
with velocity. The maximal power output depends on V ,max
 .isometric tension P and on the curvature of the force–0
w xvelocity curve 84 . The shape of the curve is dependent on
the force coefficient a, normalised to isometric forces
arP . The power output is zero during shortening without0
load at V as well as under isometric conditions. Sincemax
force and velocity are inversely related, their product will
be greatest at an intermediate load. It reaches a maximum
at around 20–40% of V while at the same time produc-max
ing around 30% of isometric tension.
P is determined by the number of attached cross-0
bridges per cross-sectional area at any given time, multi-
plied by the force development of a single cross-bridge.
The actual number of attached cross-bridges can in turn be
estimated by multiplying the total number of cross-bridges
 .n by the fraction of time spent in the force-generating
 .state duty ratio or duty cycle . V under zero loadmax
cannot be measured directly and has to be extrapolated
from the force–velocity curve, or better, may be deter-
w xmined by Edman’s slack-test 85 . Determination of iso-
metric tension of permeabilised muscle fibers yields incon-
sistent results. This may be due, at least in part, to the
 w x .experimental conditions see ref. 32 for discussion . In
 .general, the specific tension force per cross-sectional area
does not vary much among different muscles or animal
w xspecies 86,87 . In vivo, movements are seldom performed
 .at a speed close to V . The range of speed VrV atmax max
which muscles mostly work, is close to the one where the
w xmaximal power output is generated 88 . Since V of fastmax
skeletal muscle fibers is about 2–4 times higher than in
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slow fibers, the maximal power output is much lower in
w xslow than in fast fibers 89 . It has been suggested that the
maximal power output may be taken as a more reliable
index of dynamic mechanical properties of a muscle than
w xV 86 . In view of the complex muscular mechanics, themax
diversity of myosin isoform compositions may be required
to meet the physiological demands for a large number of
optimal combinations between the power output and the
corresponding shortening velocity in order to perform
movement on an economic basis.
7. Ca2H-control of cross-bridge activity
The twitch properties of fast and slow skeletal muscles
depend not only on the contractile apparatus but also on
the Ca2q-transients in the cytosol. This is even more so in
the heart. The heart muscles do not relax fully during
diastole, and neither do they contract maximally during
w x 2qsystole 90,91 . At submaximal Ca -concentrations, the
rate of tension development shows pronounced Ca2q-sensi-
tivity. The sensitivity of the myofibrillar apparatus to the
activating Ca2q is generally expressed by the pCa–tension
relation as determined under isometric steady-state condi-
tions on permeabilised fiber preparations. Some studies
have also been carried out on intact fibers using intra-
cellular Ca2q-indicators. pCa denotes the negative decadic
logarithm of the free Ca2q-concentration. The normalized
w xtension–pCa data can be fitted to the Hill equation 92
H2qw xCa
Ys H2qw xpCa q Ca50
where Y is the fractional force, pCa is the Ca2q-con-50
centration resulting in half-maximal activation, and H is
an index for cooperativity. The value of pCa provides an50
index for the affinity of Ca2q to the contractile system.
The coefficient H gives the minimal number of cooperat-
 .ing binding sites. Since cardiac troponin-C TnC contains
only one functional Ca2q-binding regulatory site, any value
of H)1 indicates cooperativity involving multiple com-
plexes of the regulatory system on the actin filament for
w x.references see 93 . Schematically, the cardiomyocyte may
 .modulate force of contraction in two ways Fig. 6 . First,
force of contraction may be altered by changing the ampli-
tude of the cytosolic Ca2q-transients. A rightward shift to
higher Ca2q-concentration from A to C on the abscissa
causes an increase in force by shifting the degree of
activation from the lower to the upper filled circle on the
 .same intermediate tension–pCa curve Fig. 6 . Second,
changes in the sensitivity of the contractile apparatus to
Ca2q may equally allow alterations in the force of contrac-
tion. A shift of the tension–pCa curve to the left or to the
right as indicated by the horizontal arrows at a given
Ca2q-concentration B, will increase or decrease the degree
Fig. 6. Schematic illustration how the cardiomyocyte may modulate
contractile force by two main mechanisms. Force is plotted versus log of
increasing Ca2q-concentrations. Increasing Ca2q from A to C increases
2q force in proportion without affecting the Ca -sensitivity filled circles on
. 2q  .the same curve . At a given Ca -concentration B open circle , force can
be increased by increasing the Ca2q-sensitivity of the contractile system
 . 2q leftward shift , or lowered by decreasing Ca -sensitivity rightward
.shift . The steepness of the force–pCa curve is a measure for cooperativ-
 .ity of the activation process Hill coefficient and is unchanged in the
given examples. For further discussion see text.
 .of activation open circles , respectively. The contractile
 .force will be altered accordingly. The Hill coefficient H
determines the steepness of the tension–pCa curve.
In general, permeabilised fibers from slow muscles
exhibit a higher Ca2q-sensitivity than fibers from fast
w xmuscles 94 . For activation levels up to around 20% of
maximal tension, increasing Ca2q seems to increase ntot
 .recruitment of cross-bridges . At higher levels of activa-
tion, Ca2q seems to increase tension by increasing f ,app
thus affecting the cross-bridge turnover kinetics directly.
These two modes of regulation do overlap, however, when
going from rest to activation. The effect of Ca2q on f isapp
consistent with the observation that Ca2q has only a small,
if any, effect on V , since this latter is mainly determinedmax
2q w xby g which is almost independent of Ca 76 . Thus,app
factors which may affect cross-bridge kinetics via f orapp
g can become important parameters for modulation ofapp
muscle activity.
8. Effects of myosin subunit isoforms on contractility
In general, V is roughly proportional to the ATPasemax
activity and speed of contraction in heart as well as in
 w x.skeletal muscles for reviews see 32,79 . The ATPase
 .activity is highest in V1 aa , intermediate in the het-
 .  .erodimer V2 ab and lowest in V3 bb cardiac isomyosin
w x 2qof a given species 31 . In skeletal muscles the Ca -sensi-
tivity is about 0.2–0.3 pCa units higher in slow than in fast
fibers. On the other hand, fast fibers exhibit a much
steeper tension–pCa curve with an H value of 4–6, while
slow fibers have one of 2–3. Human cardiac fibers from
atrium and ventricle have an equally low H value of 2–3
w x51 . This may have to do with the fact that the cardiac
TnC is also expressed in slow skeletal muscle fibers. This
cardiac TnC isoform contains only one Ca2q-binding regu-
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latory site instead of the two in the fast skeletal muscle
w x 2qTnCf 95 . In addition, the Ca -sensitivity is 0.17 units
higher in ventricular than in atrial fibers concomitant with
 .an unloaded V given as muscle length per second ofmax
2.6 for atrial and a lower one of 1.7 for ventricular fibers
w x51 . These characteristic differences seem to be mainly
due to the atrial myosin containing mainly a-MHC as
opposed to the ventricular myosin which in man contains
predominantly b-MHC. Measuring the ATPase activity
during isometric tension generation at various Ca2q-con-
centrations allows to establish the ATPase-force relation
w xfor human atrial and ventricular muscle fibers 96 . Force
at saturating Ca2q-concentrations was 14.0 for atrial and
21.1 kNrm2 for ventricular fibers. The amount of ATP
 .used per force tension cost was independent of the
Ca2q-concentration and just about three times higher for
atrial than for ventricular fibers. The Ca2q-sensitivity was
again 0.08 pCa units higher in ventricular fibers. While
both V and isometric tension generation differ onlymax
moderately between atrial and ventricular fibers, the differ-
ence in the rate of tension development is quite pro-
 .nounced. The rate constant of tension development k td
after photolytic release of ATP from ‘caged ATP’ is
seven-fold higher in atrial than in ventricular porcine
w xmuscle fibers 97 .
As outlined above, the ATPase-force relation is propor-
tional to g and the force of a muscle depends on itsapp
cross-bridge kinetics. Taken together, these results suggest
that atrial myosin cross-bridges differ in their kinetics from
the ventricular myosin by having a higher g , implying aapp
faster transition rate from force-generating into non-force
 X.generating states. If the unitary force value F were
different, one fiber type would still generate different
absolute tension at a given Ca2q-concentration, but it
should not change the normalized tension–pCa curve. A
lower g in the kinetic of V3 myosin is consistent with aapp
longer fraction of the cross-bridge cycle being spent in the
 .force-generating states increased duty ratio or duty cycle .
This difference in kinetics between human atrial and ven-
tricular myosin is thought to reside in the a-MHC and
b-MHC. It has to be born in mind, however, that these two
myosins differ in their MLC complement.
V1 and V3 myosin isoforms with the same ventricular
 .MLC complement VLC1 and VLC2 can be generated in
rabbits by making them hypothyroid producing V3 myosin
. by feeding them propylthiouracil or hyperthyroid produc-
. w xing V1 myosin by administering levothyroxine 98 . V1
myosin has twice the actin activated ATPase activity and
three times the actin filament sliding velocity in an in vitro
motility assay system, when compared to V3 myosin. Yet,
V1 myosin produces only half the average cross-bridge
force per cycle 0.15 pN for V1 and 0.30 pN for V3
.myosin . These findings also point to a kinetic difference
between the a-MHC and the b-MHC in V1 and V3
myosin, respectively. Such a difference in kinetics may
provide the molecular basis for the observation made
w xearlier by myothermal techniques 99 . The economy of
ATP utilisation for isometric force production i.e. cross-
.bridge tension–time integral per ATP by V3 was found to
be twice that for V1 myosin. The force–time integral
reflects the cross-bridge attachment time and is positively
related to economy of contraction and negatively related to
ATPase activity, shortening velocity and cross-bridge cy-
cling rate. It should be noted that slower actin translocation
velocities are not always associated with higher average
cross-bridge force. Both V1 and V3 myosin have slower
actin filament velocities than fast skeletal muscle myosin,
w xbut neither generates greater average force 100,101 .
Hyperthyroid rats supplied with triiodothyronine con-
tain exclusively a-MHC in the atria as well as in the
w xventricles 102 . There is no evidence that the tissue-
specific MLC isoforms of atrium and ventricles undergo
changes in relation to the thyroid state. The actin filament
proteins do not seem to differ between these two tissues
 w x.reviewed in 102 . Thus, atrial and ventricular my-
ocardium of hyperthyroid rats have identical composition
of myofibrillar proteins except for the tissue-specific MLC.
ATPase activities of myofibrils in solution fully stimu-
.lated at pCa 4.4 and when inhibited at pCa)8 as well as
of isolated myosin are the same in atrial and in ventricular
preparations, yet the contractile properties differ markedly
between permeabilised fibers from atrium and ventricle.
Isometric tension is 9.7 for atrial and 22.6 kNrm2 for
ventricular fibers compare corresponding values given
.above for human . Maximal shortening velocity and maxi-
mal power output are almost twice as high in atrial fibers
w x102 . These findings suggest that in addition to the MHC
also the MLC contribute to the contractile properties, while
the myofibrillar ATPase activity in solution is determined
entirely by the MHC species. The possible involvement of
the MLC in modulation of contractility and ATPase activ-
ity has recently been suggested for skeletal muscle systems
w x32,46,103 .
9. Modulation of contractility in hypertrophy by the
myosin essential light chain
The relative composition of MHC and MLC1 isoforms
in tissue samples from the free wall of all four chambers is
summarised in Table 2 for six failing human hearts five
cases with dilated cardiomyopathy, DCM, and one with
.ischemic cardiomyopathy, ICM obtained during transplan-
tation and is compared to samples from five hemodynami-
cally compensated subjects. The functional state of the
patients was characterised by the New York Heart Associ-
 .ation NYHA classification IV and by an ejection fraction
 .  .EF of 16"2% normal EF)60% . The mean pressure
 .in the right and left atrium was 14"1 normal-5 and
 .33"2 mmHg normal-12 , respectively. a-MHC and
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b-MHC can be quantified after resolution by SDS-PAGE
while two-dimensional gel electrophoresis is required for
w xquantification of the MLC isoforms 68,69 . Both ALC1
and ALC2 display a higher apparent mass than the corre-
w xsponding ventricular species 104 . For the ALC1 this
 .applies only for human and pig Fig. 4 . In most other
animals, including bovine, baboon and dogs, the ALC1 has
a lower apparent mass than VLC1.
 .The change in myosin isoforms from V1 aa to V3
 .bb in the ventricle of small animals under pressure
overload is associated with reduced ATPase activity and
V , concomitant with an increased economy of isometricmax
 w x.force development reviewed in 99 . The hemodynami-
cally overloaded human atrium seems to follow a similar
pattern. As mentioned earlier, the a-MHC gets partially
replaced by b-MHC in human atria under hemodynamic
 .overload Table 2 . In accordance, permeabilised fibers
from hypertrophic atria of patients with various valve
diseases exhibit a Ca2q-sensitivity of tension 0.16 units
w xhigher and a V 44% lower than in controls 65 . Be-max
cause of the close relation between MHC isoform and
myocardial function, energetics and biochemistry, it is
assumed that the MHC is the main determinant of the
contractile characteristics.
 .In human ventricles however, V3 bb myosin with low
ATPase activity is the predominant species under normal
conditions as also in large animals such as dog, pig,
.bovine and does not significantly change under hemody-
namic overload. The a-MHC content of the right and left
ventricles was below the biochemical detection limit both
in the hemodynamically compensated and diseased hearts
w x  .67,68 Table 2 . Nevertheless, isometric tension,
tension–time integral and maximal rate of tension rise are
2–3 times higher in muscle fibers from hypertrophic left
ventricles of patients with severe mitral regurgitation than
w x 2qin controls 99 . The Ca -sensitivity of tension was re-
cently reported to be 0.28 units higher in left ventricular
papillary muscle fibers of patients with DCM and heart
 .failure NYHA IV than in samples of subjects without
w x 2qheart affection 105 . This shift in Ca -sensitivity of
q0.28 units is even larger than those observed between
 .normal and diseased atrium q0.16 or between normal
 .atrium and normal ventricle q0.08 and q0.17 . Taken
together, these findings indicate that ventricular muscle
fibers from patients in end-stage heart failure behave me-
chanically in a similar way as do fibers from overloaded
atria where a-MHC is partially replaced by b-MHC. If a
change in expression of a myosin subunit isoform were
responsible for the altered contractility of hypertrophic
human ventricle it could only concern the reexpression of
 .ALC1 Table 2 . The ALC2 has never been detected in
normal ventricle during development, neither at high age
w x w x57 , nor in diseased ventricles 68,69 .
At mid-gestation the ALC1 constitutes roughly half of
w xthe total MLC1 in the human ventricle 106,107 . After
birth it decreases rapidly to almost zero by the age of one
year. The expression of the ALC1 persists, however, in
patients with congenital heart diseases, causing an over-
load for the right ventricle. The persistence of ALC1 in
ventricles of patients with congenital heart diseases, or its
reexpression in patients with various types of heart affec-
tions, is consistently coupled with hemodynamic overload
w x63,106,107 . The amount of ALC1 in the ventricle may
vary from a few up to over 30% of total MLC1. In 16% of
over 100 patients with hemodynamic overload ALC1 was
not detected in the ventricle.
The results of mechanical tests with permeabilised fibers
from patients containing from zero up to 20% ALC1 are
 w x.summarised in Fig. 7 data taken from Refs. 63,107 .
Material without detectable ALC1 was included from sub-
jects with normal hemodynamics. We showed for the first
time, assuming other things being equal, a positive linear
correlation between V and Ca2q-sensitivity of isometricmax
tension versus the ALC1 content. The correlation coeffi-
 . 2q  .cient r for V 12 cases and Ca -sensitivity 8 casesmax
 .is 0.82 and 0.92, respectively p-0.01 in both cases .
Thus, both these two mechanical parameters are propor-
tional to the ALC1 content. If taken together, the com-
bined regression line in Fig. 7, would have a correlation
coefficient of 0.86 with a significance level of p-0.001.
An increase of the Ca2q-sensitivity by q0.36 units and an
increase of V by a factor of 1.7 can be derived from themax
regression for an increase of 20% ALC1 in the ventricular
tissue. In addition to V , the curvature of the force–max
velocity relation changes as indicated by a decrease of the
normalised tension coefficient arP from 0.21 in fibers0
2q  2qFig. 7. Correlation of Ca -sensitivity of tension pCa , Ca required50
.for half-maximal force generation and maximal shortening velocity
 .V , expressed as muscle length per second MLrs versus ALC1max
 .content expressed as % of total MLC1 isoforms assessed on perme-
abilised ventricular muscle fibers. The regression line for pCa of left50
ventricular papillary muscle fibers from seven patients with end-stage
 .  .heart failure filled squares and one control open square has a correla-
 .tion coefficient r of 0.92 p-0.01 . The regression line for V ofmax
right ventricular infundibular muscle fibers from 11 patients with congen-
 .  .ital heart diseases filled circles and one control open circle has a
 .correlation coefficient r of 0.82 p-0.01 . The combined r for all 20
 . w xcases would be 0.86 p-0.001 . Data taken from Refs. 63,107 . For
further discussion see text.
( )M.C. Schaub et al.rCardio˝ascular Research 37 1998 381–404 393
lacking ALC1 to 0.15 in fibers containing 20% ALC1
w x107 . The rate of tension development is almost twice as
fast in fibers with high ALC1 when compared to fibers
with low ALC1 content. Isometric tension at saturating
Ca2q-concentrations was 352, 660 and 835 kNrm for
fibers with zero, 3–5% or with 20% ALC1, respectively.
All muscle specimens were treated with cardioplegic solu-
tion prior to chemical skinning and the MLC2 were thus
w xfully dephosphorylated 63,107 .
Taken together, these findings indicate that ALC1 mod-
ulates cross-bridge kinetics and thus contractility in human
ventricular muscle. Increasing ALC1 increases V whichmax
is proportional to g as well as the rate of tensionapp
 .development k which equals the sum of f qg .td app app
ALC1 thus accelerates the cycling kinetics. This may be
brought about by increasing either f or g . Which oneapp app
occurs with ALC1 cannot be decided from the measure-
w xments of V and k 107 . Either change would affectmax td
the fraction of force-generating cross-bridges, n s
 . 2qf r f qg . The Ca -sensitivity of isometric ten-app app app
sion would, however, be affected in opposite direction by
 . an increase in either f increasing it or g decreasingapp app
. w xit 76,82 . In view of the positive correlation with an
2q  .increase in Ca -sensitivity Fig. 7 , one may conclude
that ALC1 increases cross-bridge kinetics by accelerating
selectively f over g . Even if both rate constants wereapp app
increased in the presence of ALC1, f should be acceler-app
ated significantly more than g . This results in a bb-app
myosin cross-bridge with ALC1 having a longer duty
cycle fraction of time spent in force-generating states per
.ATP-cycle in conjunction with faster kinetics than normal
ventricular bb-myosin with VLC1. These kinetic charac-
teristics are compatible with the mechanics described for
ventricular muscle fibers from patients with severe mitral
 .regurgitation mentioned above for which the ALC1 con-
w xtent was not known 99 . Assuming constant unitary force
FX of bb-myosin with either MLC1, the species containing
ALC1 with a longer duty cycle would represent an eco-
nomic improvement over that with VLC1.
10. Molecular mechanism
The molecular mechanism for MLC1 to affect the
cross-bridge kinetics seems to reside in its Ala–Pro-rich
extended N-terminus which has been shown to interact
w xwith the C-terminus of actin 41,42,44 . The first hint that
the MLC1 might affect the actin–myosin interaction and
contractility came from experiments with skeletal muscles
 w x.reviewed in 45 . In vertebrate fast skeletal muscles, two
 .isoforms of the MLC1 ELC1fast and ELC2fast are ex-
pressed which result from different transcription sites and
w xdifferential splicing of the same gene 108 . The ELC2fast
is missing the N-terminal 42 amino acid residues and does
not bind to actin. V is twice as high for rabbit fast psoasmax
muscle fibers reconstituted with ELC2fast than with
w xELC1fast 45 . A similar difference in translocation veloc-
ity between myosin with either ELC2fast or ELC1fast is
w xalso observed in the in vitro motility assay system 109 .
A number of key experiments shed some light on the
molecular mechanism how the MLC1 modulates contrac-
tion in cardiac muscle. Human ALC1 can be reconstituted
 .to rabbit fast skeletal muscle myosin subfragment-1 S1
for probing its effect on the actin activated ATPase activ-
ity. Incorporated into S1, the ALC1 can also be chemically
w xcrosslinked to actin 43,47 . After removal of the first 11
residues by genetic engineering, the ALC1 can no longer
be crosslinked to actin and the ATPase kinetics resemble
those of the S1-actin complex with the short ELC2fast
isoform. In conclusion, the first 11 residues at the N-
terminus of the human ALC1 are sufficient to interact with
actin and to modulate the ATPase kinetics. It is likely that
this also applies to the human VLC1 as well as to the other
MLC1 types. Indeed, removal of the first 13 residues from
ELC1fast of chicken skeletal muscle myosin also converts
the ATPase kinetics of the S1-actin complex with ELC1fast
w xto those of S1 containing the short ELC2fast 110 . The
13-residue peptide 1-APKKDVKKPAAAA-13 was re-
moved by proteolytic cleavage with papain and is identical
in sequence to the corresponding N-terminus of the rat
 . aELC1fast Table 3 . In particular, it contains the N -tri-
methylalanine at its N-terminus like all MLC1 beginning
w xwith Ala 111 . This 13-residue peptide can itself be
crosslinked to actin and, when added to the S1-actin
complex containing the endogenous intact ELC1fast, it
 .increases the apparent Michaelis constant K as well asm
the rate of ATPase activity. This was interpreted as indicat-
ing that the binding of the 13 residue peptide to actin
prevents the normal interaction of the endogenous ELC1fast
of S1 with actin and thus converts its ATPase kinetics to
those of S1 with the short ELC2fast. Interestingly, a
synthetic decapeptide 1-APKKDVKKPA-10 missing the
N-terminal N a-trimethyl group had hardly any effect on
w xthe ATPase kinetics 110 .
All MLC1 given in Table 3 comprise four positive
charges within the first nine residues distributed over two
 .couples of Lys with one negative charge Asp or Glu in
between. Removal of the positive charges in Lys3 and
Lys4 by exchanging them for Ala by site directed mutage-
nesis in ALC1 also affects the ATPase kinetics approach-
ing those of an S1-actin complex with the short ELC2fast
w x43 . Changing the first two Lys3 and Lys4 to Ala or all
four, including also Lys7 and Lys8, leads to a gradual
increase in V of rabbit fast psoas muscle fibers aftermax
incorporation of the mutated rat ELC1fast species in com-
w xparison to fibers with its wild type ELC1fast 45 . This
demonstrates that the four positive charges among the first
nine amino acid residues of MLC1 are involved in long-
 .range electrostatic interactions salt bridges with the C-
terminus of actin. The C-terminus of actin does, indeed,
contain three negative charges in the positions 12, 13, and
 .15 from the end Table 3 . Cross-bridges with MLC1
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containing the characteristic N-terminal extension, display
a relatively slow cycling rate in comparison to the short
ELC2fast. Weakening these electrostatic interactions while
leaving the lengths of the extended N-terminus of the
MLC unchanged accelerates cross-bridge kinetics. Taken
together, these findings indicate that all long MLC1 species
attach with their extended N-terminus to actin and may
exert a mechanical drag which slows down the kinetics of
the cycling cross-bridge.
In contrast to ELC1fast, ALC1 contains one additional
 .negative charge Asp following immediately after the
 .second couple of Lys, while two negative charges Glu
 .follow in the VLC1 Table 3 . The first nine residues in
human ALC1 and VLC1 are identical in sequence. VLC1
contains Glu at position 9 instead of Asp representing a
conservative exchange. An additional negative charge fol-
lows, however, in VLC1 with Glu-11. It was recently
shown in an in vitro binding assay that a decapeptide
corresponding to the residues 4–13 of human ALC1 binds
with half the affinity to actin than the corresponding
w xdecapeptide from VLC1 112 . The weaker binding of the
ALC1 decapeptide is paralleled by faster cross-bridge ki-
netics in ventricular fibers with ALC1. These results imply
that not only the positively charged residues of the MLC1
N-terminus interact with actin, but that also the additional
negative charges in the cardiac MLC1 not present in
.skeletal muscle ELC1fast may differentially interact with
the two positive charges near the end of the C-terminus of
 .actin Table 3 .
The synthetic decapeptide 4-KPEPKKDDAK-13 of hu-
man VLC1 was used to test its effects on human cardiac
w xmuscle fibers 113 . It enhances V , rate of tensionmax
development and rate of relaxation when diffused into
intact atrial fibers. These effects are not associated with
modulation of intracellular Ca2q-transients as monitored
by the fluorescence of the Ca2q-indicator Fura-2. It further
 .increases isometric tension at submaximal pCa 5.5 and
 . 2qmaximal pCa 4.5 Ca -activation of permeabilised hu-
w xman ventricular papillary muscle fibers 113 . In addition,
this human VLC1 decapeptide induces a supramaximal
increase in the ATPase activity of rat ventricular myofib-
2q rils at submaximal Ca -levels with no effect at low pCa
. 2q  .below 7.0 and at maximal Ca -levels pCa above 5.0
w x  .114 . When troponin-I TnI and TnC were extracted from
the myofibrils, the VLC1 decapeptide lost its ability to
stimulate the ATPase rate. This effect was fully restored
w xupon reconstitution with the TnI-TnC complex 114 . Thus,
the activation of the myofibrillar ATPase activity by the
VLC1 decapeptide requires a full complement of the actin
filament regulatory proteins troponin-I, -C, -T and
.tropomyosin . Interestingly, the stimulatory effect occurs
at a ratio of 4 peptide molecules per one entire actin
filament of roughly 1 mm length and containing approxi-
mately 400 actin monomers, suggesting that the peptide
engages in a highly cooperative process. Based on these
findings it was proposed that at a submaximal level of
Ca2q the peptide analogue allows bound cross-bridges to
turn ‘on’ more actin monomers or actin filament func-
. w xtional units as opposed to without it 114 . The coopera-
tive response may be the result of peptide-induced alter-
ations in the interactions between the troponin complex,
tropomyosin and the actin strands which can spread
throughout most, or even all, of the actin filament.
It has been hypothesized that the primary function of
the extended MLC1 N-terminus may be to provide a tether
between the myosin and actin filaments. Such a tethering
would serve to position the two filament systems for
w xcross-bridge interaction 45 . This could be more important
for sarcomere assembly during development than in ma-
ture striated muscles. This, in turn, may be reflected by the
lack of expression of the short ELC2fast in early muscle
development. The extended N-terminus is required to
bridge the 8 nm gap between the bulk of the MLC1 and
the actin surface. Due to the particular sequence rich in
Ala and Pro the N-terminus is elongated and rigid prior to
 w x.its binding to actin reviewed in 47 , If it were flexible
and would assume a globular structure in the detached
state, actin binding would be accompanied by a transition
from a folded to an extended form. Such a transition would
be energetically unfavorable breaking of intramolecular
.contacts and imposition of greater order to the system
w x115 . The binding site at the end of an extended arm, as
opposed to a flexible structure, may also enhance the
association rate with actin, but leaving the dissociation rate
w xunaffected 47 .
Finally, myosin binds with its upper and lower portion
of the 50-kDa segment to two adjacent monomers in the
 . w xactin filament Fig. 3 23 . The MLC1 arm may then
reach to the second actin which is also in contact with the
lower portion of the 50-kDa, although it has not been
demonstrated yet which of the actins interacts with the
MLC1. There are then two pathways by which information
could be transmitted to the active site which is about 8 nm
w xdistant from the actin filament 23,44 , one proceeding via
the MHC in the head portion, and the other passing
through the extended MLC1 arm and travelling backwards
w xup the motor domain 47 . Taken together, these findings
give new insight into the molecular complexity and sub-
tlety of the actin–myosin interaction and its modulation of
the cross-bridge kinetics by the MLC1 not anticipated
before.
11. Pathophysiological significance of myosin essential
light chain expression in cardiac hypertrophy and fail-
ure
The human ventricular muscle contains bb-myosin with
low ATPase activity but which performs work at a higher
economic level with regard to ATP utilisation in compari-
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son to the faster contracting atrial aa-myosin. Under
hemodynamic overload, the type of MHC in the ventricle
does not, in contrast to atrial muscle, change. However, the
fetally expressed ALC1 becomes reexpressed in the ventri-
cle. This ALC1 modulates ventricular contractility by ac-
celerating the cross-bridge kinetics of bb-myosin and at
the same time, it improves the economy by prolonging the
duty ratio or duty cycle. The most significant consequence
may be the increase in Ca2q-sensitivity of the contractile
apparatus containing ALC1. This is particularly important
since myocardial contractility is governed by moderate
fluctuations in cytosolic free Ca2q-concentrations between
w xsystole and diastole 90,91 . Little or no tension is seen at
around 0.1 mM free Ca2q in the cytosol. Under rest the
heart operates only at about 25% of maximal activation
 w x.reviewed in 116 . Thus force can increase considerably
in response to increasing Ca2q-transients, even if the
Ca2q-sensitivity of the myofilaments remains unchanged.
The reexpression of ALC1 in the ventricle improves con-
tractility and can be seen as part of the adaptive response
during hypertrophy. The extent of ALC1 expression in
patients with different types of cardiac hypertrophy varies
w xconsiderably 68,69,117,118 . The observation that the ex-
tent of ALC1 accumulation correlates with the degree of
hemodynamic load the heart has to bear, but not with any
other parameter such as muscle mass or non-muscle tissue
w xcontent, points to its physiological relevance 68 . Conse-
quently, the ALC1 content was indeed reduced after suc-
cessful surgical interventions which lowered the hemody-
w xnamic overload in patients with aortic valve diseases 69 .
Although muscle specimen are often obtained from
patients with end-stage heart failure who underwent car-
diac transplantation, the ALC1 content is by no means
higher in the ventricles of these hearts than in patients in
 .the compensated phase of hypertrophy Table 2
w x63,68,69,105,107 . The question arises, however, whether
the increased contractility induced by ALC1 may turn into
maladaptation in heart failure. Heart failure is charac-
terised by decreased contractility and a low ejection frac-
 .tion around 30% or lower . A number of observations
made recently, may be at the heart of the matter. Of
foremost importance is the handling of intracellular Ca2q.
A number of proteins involved in intracellular Ca2q-
homeostasis have been shown to be lower in end-stage
failing compared to stable cardiac hypertrophy: calse-
 2qquestrin Ca -binding protein of the sarcoplasmatic retic-
. ulum, SR , the Ryanodine receptor Ca-release channel of
.  . SR , SERCA2 SR-Ca-ATPase and phospholamban regu-
. w xlatory protein of SERCA2 119 . In contrast, the Na–Ca-
w x 2qexchanger is increased 120 . Thus, more Ca is extruded
by the Na–Ca-exchanger instead of being sequestered by
the intracellular SR, and as a sequel, the myocytes in the
failing heart become impoverished on Ca2q. Consequently,
much lower systolic Ca2q-transients are seen in cardiomy-
w xocytes from human hearts in end-stage failure 121 . This,
in turn, results in blunting the normally observed fre-
w xquency potentiation of contractile force 122–124 . The
heart responds with enhanced frequency to the higher
catecholamine levels during hypertrophy, but lacks the
ability to increase contractile force. The cytosolic Ca2q-
levels are only moderately increased during diastole in
w xfailing hearts 121 and hardly affect diastolic tension
w x125 . In addition, it was recently shown in the sponta-
neously hypertrophic rat model that a defect in
 2q 2qexcitation–contraction coupling the Ca -induced Ca -
.release from SR is compensated for by the increased level
w xof circulating catecholamines 126 . Failing of this com-
pensatory mechanism due to a down-regulation of b-
w xadrenergic receptors 127 is thought to be causally linked
to the onset of heart failure in this model. The presence of
ALC1 then still represents an advantage even during heart
failure, in that it allows for a faster and larger force
development at decreased systolic Ca2q-levels in compli-
ance with a high heart rate.
On the other hand, inadequate blood supply may often
be associated with heart failure. Under such conditions, the
energy demand of the hypoperfused myocardium exceeds
the reduced energy supply. The myocardium reacts to this
imbalance by reducing its contractile function. The mecha-
nism responsible for the rapid reduction in contractile
function during myocardial ischemia remains unclear
w x128,129 . Teleologically speaking, it seems to represent an
attempt to match energy demand with supply. This perfu-
sion–contraction matching may be termed myocardial
w xstunning or hibernation 116,130 . The myocardium may
w xrecover without loss of function 131 . If it fails, however,
to reach perfusion–contraction matching, myocardial in-
farction develops. Under normal conditions, 15 to 30% of
the total energy expenditure is consumed by non-cross-
bridge processes, mainly by ion pumps sarcolemmal Na-
. 2qK-ATPase and SERCA2 to maintain the Ca -homeosta-
w xsis 1,132 . This part of energy consumption becomes
prominent in the hibernating myocardium. An insufficient
energy supply may thus affect the membrane stability and
lead to an uncontrolled increase in cytosolic Ca2q. Cytoso-
lic Ca2q-levels of 2–75 mM have been shown to occur in
ferret cardiomyocytes, at least transiently, during ischemia
w xand post-ischemic reperfusion 133 . Any increase in cy-
tosolic Ca2q above threshold level of contractile activation
during diastole causes diastolic dysfunction. This is charac-
terised by a lack of sufficient relaxation and a build-up of
the preload. Due to reduced chamber filling, the ejection
fraction may diminish. If the myocardium contains ALC1,
its increased Ca2q-sensitivity accentuates diastolic dys-
function and thus turns the originally beneficial adaptation
into maladaptation.
Elevated cytosolic Ca2q-levels may, in addition, acti-
vate non-lysosomal neutral proteinases such as m-calpain
 2q .Ca -dependent proteinase-I which requires 1–100 mM
2q w xCa for activation 134 . There are a number of sarcom-
eric proteins which are selectively susceptible to such
neutral proteinases and which have been shown to be
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degraded in terminally failing hearts. The giant protein
 .titin 3000 kDa which spans the entire half sarcomere by
w xconnecting the myosin filament with the Z-line 135 is
reduced in mRNA and protein content in failing human
w xhearts 136 . This is accompanied by the occurrence of a
titin with lower molecular mass, which probably represents
a degradation product. At the same time, myofibrillar and
cytoskeletal structures are impaired on the immunocyto-
w xchemical and electron microscopic level 137–139 .
The selective degradation of the VLC2 has been re-
ported for patients with DCM undergoing heart transplan-
w xtation 140 . Myosin isolated from these specimens dis-
played a lower actin activated ATPase activity and an
impaired capability to assemble into synthetic myosin fila-
ments in vitro. It was further shown that these hearts
contained an increased proteolytic activity specific for
w xVLC2 140 . Removal of RLCfast has been shown in
skeletal muscle fibers to slow down V and to shift themax
 2q .pCa–tension curve to the left increasing Ca -sensitivity
w x141,142 . It was concluded that removal of RLCfast slows
down g and increases, therefore, the number of forceapp
generating cross-bridges. Whether degradation of VLC2 is
typically associated with failing DCM hearts has not been
established unequivocally. We did not observe a change in
the stoichiometry of the MLC1 and MLC2 complement in
terminally failing hearts of patients with DCM or ICM
w x63,136 .
It has recently been shown in the rat experimental
model that TnI is selectively degraded in the stunned
w xmyocardium 143 . This degradation can be prevented
when stunning is followed by low Ca2q-reperfusion. Addi-
 .tion of m-calpain calpain-I to permeabilised myocardial
fibers produces identical digestion patterns. It is hypothe-
sized that the Ca2q-activated proteinase cleaves TnI in
ischemic myocardium and that this may directly impair
contractility. Ischemia and hibernation are, however, com-
plex processes in which numerous factors contribute to the
pathophysiology. Whether global or locally restricted, their
repercussions will affect, and most probably, will precipi-
tate the course of heart failure.
12. Other mechanisms modulating contractility
Changes in isoform expression of sarcomeric proteins
other than the MLC1 may also affect Ca2q-sensitivity of
 .the contractile apparatus. The cardiac troponin Tn com-
 . 2qplex comprises the inhibitory TnI , the Ca -binding
 .  .TnC and the tropomyosin binding TnT subunits. Four
w xof the 36 potential splice variants of TnT 144,145 have
w xbeen found in human hearts 146,147 . Their appearance is
developmentally regulated and TnT3c predominates in
adult human hearts. Reexpression of the fetal TnT4c iso-
form has been observed on the mRNA and protein level in
w xsome few cases of end-stage heart failure 145–148 . The
occurrence of TnT4c was associated with decreased my-
ofibrillar ATPase activity in human hearts. The Ca2q-
sensitivity of tension is also lower in permeabilised heart
muscle fibers of rats and rabbits when TnT4c is present
w x149,150 . Taken together, the fetal TnT4c isoform has the
opposite effect on Ca-sensitivity than ALC1. It is not
known whether the expression of TnT4c correlates to the
hemodynamic load. If its expression were triggered by
mechanical load as that of ALC1 seems to be, both TnT4c
and ALC1 would increase concomitantly and antagonise
each other’s effect on contractility. Since mechanical data
 .correlate linearly with the ALC1 content Fig. 7 the
possible negative effects of TnT4c, whatever its actual
concentration, would be minor. It could be that a variable
degree of expression of TnT4c contributes to the scatter of
the data.
In both normal and diseased human hearts, we found
w x  .only cardiac TnI 63 . Slow skeletal muscle TnI TnIs
mRNA may be present in infants but not in adult human
w x 2qhearts 151 . TnIs has been shown to increase Ca -sensi-
tivity of cardiac myofibrillar ATPase activity in compari-
w x son to cardiac TnI 152 . The two isoforms of TnC TnCf
in fast skeletal muscles and TnCs in heart and slow
. w xskeletal muscles originate from two different genes 153 .
Only TnCs is found in the heart. Replacement of TnCf by
TnCs reduced the Ca2q-sensitivity of tension in fast skele-
w xtal muscle fibers in vitro 154 . This transition is accompa-
nied by a decrease of the Hill coefficient from 7.7 to 2.4.
In contrast, the Hill coefficient remains unchanged around
2 with increasing ALC1 content and increasing Ca2q-sensi-
w xtivity in failing human hearts 63 . If sufficient TnCf was
expressed in failing hearts to positively affect the Ca2q-
sensitivity, the Hill-coefficient would be expected to rise
concomitantly.
Improved contractility has been shown in BALBrc
mice which express skeletal muscle a-actin in their hearts
in comparison to normal mice with mainly cordiac a-actin
w x  .155 . In human hearts both cardiac ;40% and skeletal
 .;60% a-actin isoforms are expressed. However, this
ratio does not change in patients with DCM or ICM as
w xindicated by mRNA levels 156 . Ectopic expression of the
 .b-tropomyosin b-Tm in the heart of transgenic mice
produces an increase in Ca2q-sensitivity and a decrease in
the rightward shift of the pCa–tension relation induced by
 .cAMP-dependent phosphorylation of TnI see below as
opposed to the a-Tm isoform which is normally present
w x157 . In human myocardium we find almost exclusively
the a-Tm isoform and no change in patients with compen-
w x w xsated hypertrophy 69 nor in end-stage heart failure 63 .
 .Familial hypertrophic cardiomyopathy FHC consti-
tutes a genetically heterogeneous disease. The hypertrophy
seems to be a reactive adaptation to the underlying distur-
bance of the contractile apparatus which is caused mostly
by missense or deletion mutations in any of the following
sarcomeric proteins: MHC, VLC1, VLC2, a-Tm, cardiac
 w x.MyBP-C or cardiac TnT reviewed in 5,27,54 . Most of
these mutated proteins are functionally dominant-negative
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by reducing contractility and motility in in vitro assay
systems.
A number of short-term modulatory mechanisms in-
 .volving reversible phosphorylation Table 4 affect cardiac
contractility in addition to the long-term adaptive changes
 .in gene expression. Human VLC2 164 amino acids con-
tains near its N-terminus 1-APKKAKKRAGGANSNVF-
.17 one recognition site for phosphorylation of the Ser14
 .by either myosin light chain kinase MLCK or protein
 .  .kinase-C PKC but not by protein kinase-A PKA
w x  .128,158,159 . The three basic residues KKR upstream of
Ser14 and the highly conserved three residues following
 .Ser14 NVF constitute the substrate specificity for MLCK.
In addition, all vertebrate RLC contain the two adjacent
 .Lys K near their N-terminus. Thus the clusters of posi-
tive charges are reminiscent of those in the MLC1 iso-
 .forms compare Table 3 . These positive charges near the
N-terminus may in both cases facilitate to contact the
 .binding site of the reaction partner: i the proximate actin
 .monomer in the case of MLC1 as discussed above and
 .ii MLCK in the case of MLC2. Phosphorylation of both
VLC2 and ALC2 affects contractility by increasing the
Ca2q-sensitivity of force development as well as ATPase
w xactivity 97,160–163 . This seems to be achieved by an
increase in the rate f of the transition from non-force toapp
w xforce-generating cross-bridges 97 . ALC2 can also be
bis-phosphorylated, however, the physiological signifi-
w xcance of this feature is not known 53 . Sequence data are
not yet available for ALC2.
Phosphorylation of TnI by PKA which results from
b-adrenergic stimulation, leads to a decrease in the sensi-
tivity of the contractile proteins to Ca2q which is accom-
panied by an increase in cross-bridge cycling rate re-
w x.viewed in 128 . Cardiac TnI is thought to exert its effects
by reducing the affinity of TnCs for Ca2q. This may
function as a negative feed-back mechanism by accelerat-
ing the relaxation rate of the beating heart under the
w xinfluence of b-adrenergic stimulation 164 . Human car-
diac TnI contains 209 amino acids with a 31 residue
extension at its N-terminus found neither in the fast nor in
w xthe slow skeletal isoforms 165 . Phosphorylation of the
two adjacent Ser22rSer23 is required for these effects
 . w xTable 4 166 . This represents an interesting situation
where the tissue-specific hormonal response is discrimi-
nated not at the receptor level at the cell surface, but inside
the cell by a particular amino acid sequence in the target
protein which is not present in the isoforms of other
muscle tissues. The same principle applies also to the
cardiac isoform of the myosin binding protein-C see
.below . In addition, cardiac TnI as well as TnT can be
phosphorylated at multiple sites by PKC isoforms Table
.4 . In general, phosphorylation of either cardiac TnI or
TnT by PKC isoforms reduces Ca2q-sensitivity and actin
w xactivated ATPase activity 167 .
The a-Tm can also be phosphorylated at its penultimate
Ser283 which enhances the actin activated ATPase activity
2q w xwithout changing the Ca -sensitivity 168 . This phospho-
rylation site lies in the region where two adjacent Tm
molecules join head-to-tail together by overlapping with
about 9 residues. The N-terminal portion of TnT which
connects the Tn complex to Tm also makes contact in this
w xregion 168 . Responsible for a-Tm phosphorylation is a
Tm kinase which does not require Ca2q, calmodulin nor
w x cAMP 169 . The myosin binding protein-C MyBP-C, 137
.  .kDa Figs. 1 and 2 is the only protein in the myosin
w xfilament that can be phosphorylated by PKA 128,170 .
 .Human cardiac MyBP-C 1173 amino acids contains a
nine-residue specific loop 174-LAGGGRRIS-182 in the
N-terminal region which can be reversibly phosphorylated
upon b-adrenergic stimulation and which is not present in
w xthe skeletal muscle isoforms 171 . As a consequence, the
cardiac MyBP-C can be phosphorylated at four sites in
contrast to only one such site in the skeletal muscle
 .isoforms Table 4 . One of the four sites in cardiac MyBP-C
 .Ser182 located in the cardiac-specific loop needs to be
phosphorylated first by a Ca2q-calmodulin dependent pro-
 .tein kinase CAMK before PKA is able to phosphorylate
 . w xthe remaining three sites Ser173rSer202rThr261 171 .
MyBP-C can also be phosphorylated by PKC. Both PKA
and PKC have been shown to phosphorylate the same sites
Table 4
Phosphorylation of cardiac sarcomeric proteins by various protein kinases. Phosphorylation sites are given where known and numbered according to human
protein sequences. These phosphorylation reactions have been shown to occur in adult cardiomyocytes. For discussion see text
Protein kinase Cardiac protein Phosphorylation sites Ca-sensitivity of contractility Ref.
or activation of ATPase activity
w xMLCKrPKC VLC2 Ser14 › 159
w xPKA TnI Ser22rSer23 x 167,185
w xPKC-a TnI Ser41rSer43rThr142 x 167,185
w xPKC-d TnI Ser22rSer23rSer41rSer42rThr142 x 167,185
w xPKC-z TnT multiple sites x 185
w xTm kinase a-Tm Ser283 › 168,169
w xCAMK MyBP-C Ser182 ? 171
w xPKArPKC MyBP-C Ser173rSer202rThr261 › 170–172
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w xon cardiac MyBP-C 172 . Phosphorylation of MyBP-C
provokes the cross-bridges to extend from the backbone of
w xthe myosin filament 170 . This could facilitate cross-bridge
attachment to the actin filament and thereby modify the
kinetics of force generation in activated cardiac muscle. Its
specific effect on contractility is not known at present,
since no method exists for removal and reconstitution of
MyBP-C in isolated contractile systems. In situ phosphory-
lation of MyBP-C cannot be controlled selectively without
affecting other sarcomeric proteins as well.
Finally, cardiac contractility is also influenced by
changes in sarcomere length and variations in intracellular
metabolites. Lowering of intracellular pH and accumula-
tion of inorganic phosphate Pi are known to lower Ca2q-
sensitivity of force. It has recently been shown that the
pH-dependent influence on the Ca2q-sensitivity is medi-
ated by TnI which modulates the binding affinity of Ca2q
w xto cardiac TnC 173 . During hypoxia accumulation of
w xintracellular Pi may reach levels higher than 5 mM 174 .
This leads to reduced tension generation at unchanged or
2q w xincreased intracellular Ca -transients 175,176 . In normal
heart muscle as well as during hypertrophy the Ca2q-sensi-
tivity significantly increases with stretch, i.e. with increas-
ing sarcomere length. This phenomenon provides the basis
for the Frank–Starling mechanism which is one of the
most important regulatory devices in controlling cardiac
contractility from beat-to-beat. The length-dependent
change in Ca2q-sensitivity of permeabilised cardiac muscle
fibers correlates more closely to the change in interfila-
ment spacing than to the change in sarcomere length
w x177,178 . The narrowing of the interfilament lattice spac-
ing during lengthening seems to facilitate cross-bridge
attachment to the actin filament. Replacement of endoge-
nous cardiac TnC by the skeletal muscle isoform of TnC
results in a reduction of the length dependence of cardiac
w xfibers to the level of skeletal muscle fibers 179 . The
lowered length dependence can be reversed to the original
cardiac level by reconstitution with a TnC chimera con-
taining the first 41 amino acid residues of cardiac TnC
spliced onto the skeletal muscle isoform. Ectopic expres-
sion of skeletal muscle TnC in the hearts of transgenic
mice did, however, not change the Ca2q-sensitivity of
w xtension in these hearts 177 . There is some controversy in
the literature whether or not this mechanism is operative in
the failing heart. Left ventricular papillary muscle strips
from patients with DCM and heart failure failed to in-
crease force upon increasing preload when electrically
driven at 1 Hz and 378C, as did those from non-failing
w xhearts 105 . Permeabilised muscle fibers from the same
failing hearts displayed a higher Ca2q-sensitivity than con-
trols, a sensitivity however, which did not further increase
under pre-stretch. This is in contrast to a recent study in
which an unchanged positive Frank–Starling mechanism
was demonstrated in hearts of patients with end-stage
w xfailure suffering from DCM or ICM 180 . Mechanical
tests were done on whole left ventricles, on isolated intact
muscle strips and on permeabilised fibers. The reason for
the different results is not clear. One wonders, whether
such differences may be due to degradation processes
either in the contractile or cytoskeletal structures stemming
from in vivo stages or occurring during sample prepara-
tion.
13. Conclusions and outlook
We have first reported that the reexpression of ALC1 in
human ventricle during hypertrophy is related to the de-
w xgree of hemodynamic load 68,69 . We are now able to
explain the underlaying molecular mechanism for the im-
proved ventricular contractility by ALC1. ALC1 enhances
cross-bridge kinetics in such a way that force generation is
increased at a given cytosolic Ca2q-concentration. This
functional effect can be traced to the particular primary
structure of the ALC1 which modulates the interaction of
myosin with the actin filament during the cross-bridge
cycle.
In addition, covalent protein modification by reversible
phosphorylation may transiently affect contractility, but it
does so in a complex manner. Increased b-adrenergic
stimulation is characteristic for hypertrophy as well as for
heart failure. This stimulation mainly operates via the
adenylate cyclasercAMPrcAMP-dependent PKA system
 w x.reviewed in 8 . Increased PKA activity is known to
 . 2qinduce phosphorylation of i Ca -channels in the sar-
 . colemma, ii phospholamban regulatory protein of
.  .SERCA2 and iii sarcomeric proteins TnI and MyBP-C
 w x.reviewed in 181 . This results in a higher intracellular
Ca2q-level. The phosphorylated TnI attenuates contractil-
2q  .ity. The increased Ca together with calmodulin stimu-
lates the activity of MLCK and increases MLC2 phospho-
rylation. Phosphorylated MLC2 promotes contractility and
thus counteracts the attenuating effect of phosphorylated
TnI. Ca2q-calmodulin is also required for activation of
CAMK which, in turn, allows for the sequential phospho-
rylation of MyBP-C by PKA which may also enhance
contractility. On the other hand, a number of G-protein
coupled receptor systems including muscarinic choliner-
.gic, angiotensin-II, endothelin-1 and a-adrenergic in the
w xcardiomyocyte induce PKC activation 8,172 . PKC phos-
phorylates TnT and TnI at various sites depending on the
isoform species. PKC furthermore, competes with MLCK
and PKA for phosphorylation of the same sites in MLC2
 .and MyBP-C, respectively Table 4 . The interconnection
between different signaling pathways involving various
kinds of protein kinases which may result in identical
phosphorylation of several target proteins, seems at first
sight to comprise some redundancy. However, in view of
the multifactorial etiology that leads to hypertrophy and
heart failure, the cardiomyocyte depends on a complex
( )M.C. Schaub et al.rCardio˝ascular Research 37 1998 381–404 399
repertoire of mechanisms for modulating and fine-tuning
its contractile responses to varying demands.
In conclusion, the short-term regulatory processes of
cardiomyocytes may vary rapidly with time in response to
global changes in the whole body or to local changes in
the heart muscle. These rapid changes may enhance or
restrict contractility in accordance with temporary de-
mands and energy supply. The adaptive long-lasting
changes in gene expression provide the basis the short-term
modulatory processes may act upon. The particular state in
which the myocyte finds itself, thus, determines whether
the increased Ca2q-sensitivity of the contractile apparatus
brought about by the expression of ALC1 in the hyper-
trophic ventricle may be beneficial or detrimental in the
event of heart failure.
In the near future we will have to learn more about
molecular mechanisms of normal and compromised heart
function. This may be pursued by two main routes of
 .research involving i transgenic animals with either abla-
 .tion or overexpression of specific genes, and ii primary
cultures of cardiomyocytes and other heart cells as an in
vitro model system for the hypertrophy reaction. The first
approach gives information on functional alterations in the
intact organism with all its complex responses and com-
pensatory mechanisms. The second approach allows to
study the effects of single hypertrophic stimuli such as
hormones, growth factors, cytokines, vasoactive peptides
.as well as mechanical stress under defined conditions on
w xcell morphology as well as on gene expression 5,7,8 .
Today, primary culture systems still have to be used as
long as no viable established myocardial cell lines exist.
This arises from the fact that the cell cycle of the termi-
nally differentiated cardiomyocytes is blocked. A further
goal in heart research will certainly be to overcome this
block by interference with the cell cycle control mecha-
nisms. This could eventually open the possibility to com-
pensate cardiovascular overload by controlled hyperplasia
 .proliferation of cardiomyocytes rather than hypertrophy
alone. As long as this route is barred, it seems desirable to
better control the hypertrophy reaction by furthering the
positive and minimizing the negative aspects. To this end,
the gene expression pattern needs changing. That may be
achieved by either administering drugs such as cell media-
tors and anti-sense oligonucleotides, or by somatic gene
transfer. Overexpression of several genes in the heart has
been shown recently to augment cardiac performance in
w xlaboratory animal models 182 . If the latter approach were
taken, it has to be born in mind, however, that overexpres-
sion of a particular gene should be driven by a promoter
which is specific for human ventricular tissue. In sum-
mary, detailed knowledge of the molecular mechanisms
connected with the hypertrophy reaction and its transition
into heart failure is a prerequisite for the development of
new potential therapeutic strategies as well as of more
adequate animal models to test them in vivo.
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